Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Jubilant Life Sciences — Q4 FY2020 Earnings Presentation
23 slides from Jubilant Pharmova's earnings presentation, May 29, 2020
Slide 1: Financial Results Quarter & Year Ended March 31, 2020
Financial Results Quarter & Year Ended March 31, 2020
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : May 29, 2020 Time : 05:00 pm IST Replay from : May 29 to June 05, 2020 Dial in No.: +91 22 7194 5757 Playback ID: 95201# 22
Slide 4: Chairmen’s Message
Chairmen’s Message JUBILANT Q4’FY20 & FY20 PERFORMANCE FY20 Revenue at Rs 9,154 Crore; Q4’FY20 Revenue at Rs 2,391 Crore FY20 EBITDA at Rs 1,995 Crore up 12% YoY; Q4’FY20 EBITDA at Rs 556 Crore up 58% YoY Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-C
Slide 5: Update on Reorganization Proposal
Update on Reorganization Proposal ◼ Post the board approval on Oct 25, 2019 for reorganizing the businesses of the Company, in November 2019, the Company had filed with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) the Composite Scheme of Arrangement for amalgamation of certai
Slide 6: Q4’FY20 Results Analysis
Ww Mirescncts Q4’FY20 Results Analysis
Slide 7: JLL – Q4’FY20 Financial Highlights
JLL – Q4’FY20 Financial Highlights YoY 1 Particulars Q4'FY19 Q4'FY20 ▪ Revenue at Rs 2,391 Crore, as compared with Rs 2,386 Crore in Q4’FY19 Change (%) Revenue • Pharmaceuticals revenue at Rs 1,483 Crore, an increase of 6% YoY, contributing 62% Pharmaceuticals 2 1,405 1,483 6% to revenue Life Scienc
Slide 8: Pharmaceuticals Segment Highlights – Q4’FY20 (1/2)
Pharmaceuticals Segment Highlights – Q4’FY20 (1/2) Particulars1 Q4'FY19 Q4'FY20 % Change ▪ Pharmaceuticals revenue at Rs 1,483 Crore, an increase of 6% YoY and Revenue 1,405 1,483 6% 2% QoQ. Specialty Pharma and Generics segments increased by 13% YoY Specialty Pharma 695 787 13% and 17% YoY, respect
Slide 9: Pharmaceuticals Segment Highlights – Q4’FY20 (2/2)
Pharmaceuticals Segment Highlights – Q4’FY20 (2/2) USFDA Inspection Details Generics1 (21% of Pharma Revenues) • Revenue was up 17% YoY and 5% QoQ due to better performance in the Facility Last Inspection US market, which witnessed higher volumes and better prices Montreal, CMO May, 2018 • Establish
Slide 10: LSI Segment Highlights – Q4’FY20
LSI Segment Highlights – Q4’FY20 1 Particulars Q4'FY19 Q4'FY20 % Change ▪ LSI revenue at Rs 823 Crore, decreased by 10% YoY and increased by 3% Revenue 912 823 (10%) QoQ. Though Strong growth witnessed in Nutritional Products however Specialty Intermediates 328 286 (13%) Specialty Intermediates busi
Slide 11: Drug Discovery & Development Solutions – Q4’FY20
Drug Discovery & Development Solutions – Q4’FY20 1 Particulars Q4'FY19 Q4'FY20 % Change ▪ Drug Discovery & Development Solutions (DDDS) comprises Revenue 68 85 25% Drug Discovery Services 68 85 25% • Drug Discovery Services business through Jubilant Biosys Proprietary Drug Discovery 0 0 - Limited &
Slide 12: Proprietary Drug Discovery (Jubilant Therapeutics)
Proprietary Drug Discovery (Jubilant Therapeutics) ▪ Jubilant Therapeutics is a patient-focused biopharmaceutical company working to address unmet medical needs in oncology and autoimmune diseases. Our advanced discovery engine integrates structure-based design and computational architecture to disc
Slide 13: FY20 Results Analysis
Ww Mirescncts FY20 Results Analysis 12
Slide 14: JLL – FY20 Financial Highlights
JLL – FY20 Financial Highlights YoY 1 Particulars FY19 FY20 Change (%) ▪ Revenue at Rs 9,154 Crore up from Rs 9,111 Crore in FY19 Revenue • Pharmaceuticals revenue at Rs 5,714 Crore, increased by 7% YoY, Pharmaceuticals 2 5,349 5,714 7% contributing 62% to revenue Life Science Ingredients 3,545 3,17
Slide 15: Adjusted Earnings
Adjusted Earnings Rs Crore Consol EBITDA % Change % Change S. No. Particulars Q4'FY19 Q4'FY20 YoY FY19 FY20 YoY 1 Reported EBITDA 351 556 58% 1,775 1,995 12% 2 One-off Adjustments 37 12 85 72 3 Adjusted EBITDA 388 568 46% 1,860 2,066 11% 4 Reported EBITDA Margin 14.7% 23.3% 19.5% 21.8% 5 Adjusted EB
Slide 16: Pharmaceuticals Segment Highlights – FY20
Pharmaceuticals Segment Highlights – FY20 1 Particulars FY19 FY20 % Change Geography Wise Revenue1 Revenue 5,349 5,714 7% Specialty Pharma 2,830 3,019 7% 4,730 4,289 Radiopharma 2,467 2,608 6% Allergy Therapy Products 362 411 14% CDMO 1,470 1,536 5% 148 137 541 473 371 375 CMO 785 896 14% API 685 64
Slide 17: LSI Segment Highlights – FY20
LSI Segment Highlights – FY20 Particulars1 FY19 FY20 % Change ▪ LSI revenue at Rs 3,179 Crore decreased by 10% YoY. Strong Revenue 3,545 3,179 (10%) growth witnessed in Specialty Intermediates and Nutritional Specialty Intermediates 1,011 1,117 10% Nutritional Products 410 537 31% Products amid lowe
Slide 18: Drug Discovery & Development Solutions – FY20
Drug Discovery & Development Solutions – FY20 1 Particulars FY19 FY20 % Change ▪ DDDS segment revenue increased 21% YoY to Rs 262 Revenue 217 262 21% Crore led by growth in Drug Discovery Services Drug Discovery Services 217 262 21% business, which was driven by higher demand from Proprietary Drug D
Slide 19: Debt Profile
Debt Profile Particulars 31/03/19 30/12/19 31/03/20 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Subsidiaries 500 400 431 Total 500 400 431 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 1,341 1,156 1,295 Subsidiaries 61 37 100 Total 1,402 1,193 1,395 Gross Debt (Rs. Crs) (Rs. Crs) (Rs. Crs) St
Slide 20: Jubilant Life Science – Strategic Priorities
Jubilant Life Science – Strategic Priorities ▪ The Company’s strategic focus is to further strengthen its leadership position in all its businesses while creating value for its shareholders ▪ Despite the Covid-19 impacts all around, we have taken several steps to ensure uninterrupted supplies to our
Slide 21: Appendix
Ww Mirescncts Appendix 20
Slide 22: Income Statement – Q4 & 12M’FY20
Income Statement – Q4 & 12M’FY20 Particulars1 Q4'FY19 Q4'FY20 YoY Growth FY19 FY20 YoY Growth Total Revenue from Operations 2,386 2,391 0% 9111 9,154 0% Pharmaceuticals 1,405 1,483 6% 5349 5,714 7% Life Science Ingredients 912 823 (10%) 3545 3,179 (10%) Drug Discovery & Development Solutions 68 85 2
Slide 23: For more information
For more information For Investors: Vineet V Mayer Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1021 Ph: +91 22 6645 1209 E-mail: vineet.mayer@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Desiree Crasto Jubilant Life Sciences Limited Madison Pub
Jubilant Life Sciences — Q4 FY2020 Earnings Presentation on 6ix